DE69434403D1 - Behandlung von immunologischen und hematologischen störungen mit igfbp allein oder als komplex mit igf - Google Patents

Behandlung von immunologischen und hematologischen störungen mit igfbp allein oder als komplex mit igf

Info

Publication number
DE69434403D1
DE69434403D1 DE69434403T DE69434403T DE69434403D1 DE 69434403 D1 DE69434403 D1 DE 69434403D1 DE 69434403 T DE69434403 T DE 69434403T DE 69434403 T DE69434403 T DE 69434403T DE 69434403 D1 DE69434403 D1 DE 69434403D1
Authority
DE
Germany
Prior art keywords
igfbp
igf
complex
treatment
immunological
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69434403T
Other languages
English (en)
Other versions
DE69434403T2 (de
Inventor
Joseph A Carlino
Howard R Higley
Christopher A Maack
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celtrix Pharmaceuticals Inc
Original Assignee
Celtrix Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celtrix Pharmaceuticals Inc filed Critical Celtrix Pharmaceuticals Inc
Publication of DE69434403D1 publication Critical patent/DE69434403D1/de
Application granted granted Critical
Publication of DE69434403T2 publication Critical patent/DE69434403T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
DE69434403T 1993-09-20 1994-09-20 Behandlung von immunologischen und hämatologischen Störungen mit IGFBP allein oder als Komplex mit IGF Expired - Fee Related DE69434403T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12441093A 1993-09-20 1993-09-20
US124410 1993-09-20

Publications (2)

Publication Number Publication Date
DE69434403D1 true DE69434403D1 (de) 2005-07-14
DE69434403T2 DE69434403T2 (de) 2006-05-04

Family

ID=22414706

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69431631T Expired - Fee Related DE69431631T2 (de) 1993-09-20 1994-09-20 Behandlung von hematologischen störungen mit einem igf-1/igfbp-3 komplex
DE69434403T Expired - Fee Related DE69434403T2 (de) 1993-09-20 1994-09-20 Behandlung von immunologischen und hämatologischen Störungen mit IGFBP allein oder als Komplex mit IGF

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE69431631T Expired - Fee Related DE69431631T2 (de) 1993-09-20 1994-09-20 Behandlung von hematologischen störungen mit einem igf-1/igfbp-3 komplex

Country Status (9)

Country Link
US (1) US5527776A (de)
EP (2) EP1238674B1 (de)
JP (1) JPH09507832A (de)
AT (2) ATE226958T1 (de)
AU (1) AU688793B2 (de)
CA (1) CA2172158A1 (de)
DE (2) DE69431631T2 (de)
ES (1) ES2241906T3 (de)
WO (1) WO1995008567A1 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5712249A (en) * 1994-09-08 1998-01-27 Ciba-Geigy Corporation Use of insulin-like growth factors I and II for inhibition of inflammatory response
US5741776A (en) * 1995-05-22 1998-04-21 Genentech, Inc. Method of administration of IGF-I
US6514937B1 (en) 1997-02-25 2003-02-04 Celtrix Pharmaceuticals, Inc. Method of treating psychological and metabolic disorders using IGF or IGF/IGFBP-3
US6025368A (en) * 1997-02-25 2000-02-15 Celtrix Pharmaceuticals, Inc. Method for treating the symptoms of chronic stress-related disorders using IGF
US6015786A (en) * 1997-02-25 2000-01-18 Celtrix Pharmaceuticals, Inc. Method for increasing sex steroid levels using IGF or IGF/IGFBP-3
US6436897B2 (en) 1998-06-01 2002-08-20 Celtrix Pharmaceuticals, Inc. Pharmaceutical formulations for IGF/IGFBP
US6417330B1 (en) 1998-06-01 2002-07-09 Celtrix Pharmaceuticals, Inc. Insulin-like growth factor binding protein variants
US7288516B1 (en) 1999-09-20 2007-10-30 Celtrix Pharmaceuticals, Inc. Null IGF for the treatment of cancer
EP1117425A2 (de) * 1998-10-02 2001-07-25 Celtrix Pharmaceuticals, Inc. Verfahren zur behandlung von nichtthyroidstörungen
US6040292A (en) * 1999-06-04 2000-03-21 Celtrix Pharmaceuticals, Inc. Methods for treating diabetes
NZ515964A (en) * 1999-06-21 2004-03-26 Murdoch Childrens Res Inst A method for the prophylaxis and/or treatment of medical disorders
US6468290B1 (en) 2000-06-05 2002-10-22 Scimed Life Systems, Inc. Two-planar vena cava filter with self-centering capabilities
AU2001291090B2 (en) * 2000-09-19 2007-05-10 Bioexpertise, Llc Method for use of IGF-binding protein for selective sensitization of target cells in vivo
US6841386B2 (en) 2001-04-10 2005-01-11 Viacell, Inc. Modulation of primary stem cell differentiation using an insulin-like growth factor binding protein
US6914049B2 (en) * 2001-09-18 2005-07-05 Bioexpertise, Llc IGF-binding protein-derived peptide or small molecule
US6887851B2 (en) * 2001-09-18 2005-05-03 Bioexpertise, Llc IGF-binding protein-derived peptide
EP1435986B1 (de) * 2001-09-18 2008-01-02 Bioexpertise, Llc Von igf-bindungsprotein stammendes peptid
US20050148509A1 (en) * 2003-07-09 2005-07-07 The University Of Iowa Research Foundation Binding proteins as chemotherapy
US10022212B2 (en) 2011-01-13 2018-07-17 Cook Medical Technologies Llc Temporary venous filter with anti-coagulant delivery method

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL71991A (en) * 1983-06-06 1994-05-30 Genentech Inc Preparation of human FGI and FGE in their processed form through recombinant AND tranology in prokaryotes
US4876242A (en) * 1987-09-21 1989-10-24 Merck & Co., Inc. Human insulin-like growth factor analoges with reduced binding to serum carrier proteins and their production in yeast
JP2507106B2 (ja) * 1987-12-24 1996-06-12 グロペップ プロプライエタリー リミテッド インスリン様成長因子１（ｉｇｆ―１）または因子２（ｉｇｆ―２）の類縁ペプチド
GB8826451D0 (en) * 1988-11-11 1988-12-14 Sandoz Ltd Improvements in/relating to organic compounds
DE69233155T2 (de) * 1991-01-08 2004-06-03 Chiron Corp. (N.D.Ges.D. Staates Delaware), Emeryville Insulinartigen wachstumsfaktor bindendes protein
US5187151A (en) * 1991-02-12 1993-02-16 Genentech, Inc. Use of binding protein with igf-i as an anabolic growth promoting agent
US5202119A (en) * 1991-06-28 1993-04-13 Genentech, Inc. Method of stimulating immune response

Also Published As

Publication number Publication date
EP1238674B1 (de) 2005-06-08
EP0726911A1 (de) 1996-08-21
EP0726911A4 (de) 1997-02-26
DE69431631D1 (de) 2002-12-05
AU688793B2 (en) 1998-03-19
ATE226958T1 (de) 2002-11-15
CA2172158A1 (en) 1995-03-30
DE69431631T2 (de) 2003-07-31
ES2241906T3 (es) 2005-11-01
US5527776A (en) 1996-06-18
WO1995008567A1 (en) 1995-03-30
AU7731494A (en) 1995-04-10
JPH09507832A (ja) 1997-08-12
EP0726911B1 (de) 2002-10-30
ATE297214T1 (de) 2005-06-15
EP1238674A2 (de) 2002-09-11
DE69434403T2 (de) 2006-05-04
EP1238674A3 (de) 2002-10-23

Similar Documents

Publication Publication Date Title
ATE297214T1 (de) Behandlung von immunologischen und hematologischen störungen mit igfbp allein oder als komplex mit igf
ATE141928T1 (de) Osteoinduktive mittel
GR3007092T3 (de)
ES2140463T3 (es) Prevencion y tratamiento de la neuropatia periferica.
DE68905205D1 (de) Verwendung von igf-i zur herstellung eines praeparats fuer die behandlung und die verhuetung von nebeneffekten von hyperinsulinemia bei diabetikern behandelt mit insulin.
DE69231971D1 (de) Lösungen zur Oberflächenbehandlung von Halbleitern
ZA916B (en) Composition and method for the treatment of osteoporosis in mammals
CA2117193A1 (en) Vaccine comprising part of constant region of ige for treatment of ige-medicated allergic reactions
ES2174852T3 (es) Metodo para el tratamiento sistemico de estados catabolicos y lesiones sistemicas de tejidos.
ES2144527T3 (es) Metodo para el tratamiento de disfunciones en la reproduccion.
DE59202695D1 (de) Mittel zur Oberflächenbehandlung von Dentalteilen, insbesondere Schleif-, Polier- und/oder Strahlmittel.
NO903322D0 (no) Fremgangsmaate for behandling av huder og huder oppnaadd derved.
EP0596034A4 (de) Reinigung von ciliary neurotrophic factor (cntf) und von c-terminal verkürzten cntf und verfahren zur behandlung von schädigungen peripheren nerven.
ATA119394A (de) Verwendung von humanem protein c zur verhinderung und behandlung von thrombozytenablagerungen
DE3768595D1 (de) Einrichtung zur kontrolle und behandlung von gegenstaenden.
DE69512986D1 (de) Behälter zur koninuierlichen Nassbehandlung von in Bandform angeordneten Fäden oder Garnen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee